-
EP2498773
European procedure
Extract from the Register of European Patents
EP About this file: EP2498773
| EP2498773 - COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT LEUKAEMIA AND/OR OF POTENTIALLY CHEMORESISTANT LEUKAEMIA [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 03.06.2016 Database last updated on 29.06.2024 | Most recent event Tooltip | 19.10.2018 | Lapse of the patent in a contracting state New state(s): AL | published on 21.11.2018 [2018/47] | Applicant(s) | For all designated states Noi Per Voi Onlus Sez. Onco-Ematologia Villa Ognissanti Cini 24 50139 Careggi (FI) / IT | [2012/38] | Inventor(s) | 01 /
ARCANGELI, Annarosa c/o Università di Firenze Dipartimento di Patologia e Oncologia Sperimentali Viale Morgagni 50 I-50134 Firenze / IT | 02 /
BECCHETTI, Andrea c/o Università di Milano Bicocca Dipartimento di Biotecnologie e Bioscienze Piazza della Scienza 2 I-20126 Milano / IT | 03 /
PILLOZZI, Serena c/o Università di Firenze Dipartimento di Patologia e Oncologia Sperimentali Viale Morgagni 50 I-50134 Firenze / IT | 04 /
MASSELLI, Marika c/o Università di Firenze Dipartimento di Patologia e Oncologia Sperimentali Viale Morgagni 50 I-50134 Firenze / IT | 05 /
DE LORENZO, Emanuele c/o Università di Firenze Dipartimento di Patologia e Oncologia Sperimentali Viale Morgagni 5 I-50134 Firenze / IT | [2012/38] | Representative(s) | Predazzi, Valentina, et al Società Italiana Brevetti S.p.A. Piazza di Pietra, 39 00186 Roma / IT | [2015/31] |
| Former [2012/38] | Predazzi, Valentina, et al Società Italiana Brevetti S.p.A. Piazza di Pietra, 39 00186 Roma / IT | Application number, filing date | 10807721.5 | 10.11.2010 | WO2010IB55112 | Priority number, date | IT2009RM00578 | 10.11.2009 Original published format: IT RM20090578 | IT2010RM00048 | 09.02.2010 Original published format: IT RM20100048 | [2012/38] | Filing language | IT | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2011058508 | Date: | 19.05.2011 | Language: | EN | [2011/20] | Type: | A2 Application without search report | No.: | EP2498773 | Date: | 19.09.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.05.2011 takes the place of the publication of the European patent application. | [2012/38] | Type: | B1 Patent specification | No.: | EP2498773 | Date: | 29.07.2015 | Language: | EN | [2015/31] | Search report(s) | International search report - published on: | EP | 06.10.2011 | Classification | IPC: | A61K31/4184, A61K31/454, A61K31/4545, A61K31/519, A61K31/573, A61K31/704, A61K31/7048, A61K45/06, A61K38/50, A61P35/02, G01N33/50, G01N33/68, G01N33/574, C07K16/18 | [2015/14] | CPC: |
A61K31/7048 (EP,US);
A61K31/4184 (EP,US);
A61K31/454 (EP,US);
A61K31/4545 (EP,US);
A61K31/519 (EP,US);
A61K31/573 (EP,US);
A61K31/704 (EP,US);
A61K38/50 (EP,US);
A61K45/06 (EP,US);
A61P35/00 (EP);
A61P35/02 (EP);
C07K16/18 (EP,US);
| C-Set: |
A61K31/4184, A61K2300/00 (US,EP);
A61K31/4545, A61K2300/00 (US,EP);
A61K31/454, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (US,EP);
A61K31/573, A61K2300/00 (EP,US);
A61K31/7048, A61K2300/00 (EP,US); |
| Former IPC [2012/38] | A61K31/4184, A61K31/454, A61K31/4545, A61K31/519, A61K31/573, A61K31/704, A61K31/7048, A61K45/06, A61K38/50, A61P35/02, G01N33/50, G01N33/68 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/38] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON CHEMORESISTENTER LEUKÄMIE UND/ODER VON POTENZIELL CHEMORESISTENTER LEUKÄMIE | [2012/38] | English: | COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT LEUKAEMIA AND/OR OF POTENTIALLY CHEMORESISTANT LEUKAEMIA | [2012/38] | French: | NOUVELLES COMPOSITIONS POUR LE TRAITEMENT DE LEUCÉMIES CHIMIORÉSISTANTES ET/OU POTENTIELLEMENT CHIMIORÉSISTANTES | [2012/38] | Entry into regional phase | 08.06.2012 | National basic fee paid | 08.06.2012 | Designation fee(s) paid | 08.06.2012 | Examination fee paid | Examination procedure | 08.06.2012 | Amendment by applicant (claims and/or description) | 08.06.2012 | Examination requested [2012/38] | 21.05.2013 | Despatch of a communication from the examining division (Time limit: M06) | 02.12.2013 | Reply to a communication from the examining division | 28.01.2015 | Despatch of a communication from the examining division (Time limit: M02) | 10.02.2015 | Reply to a communication from the examining division | 13.03.2015 | Communication of intention to grant the patent | 19.05.2015 | Fee for grant paid | 19.05.2015 | Fee for publishing/printing paid | 19.05.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 21.05.2013 | Opposition(s) | 02.05.2016 | No opposition filed within time limit [2016/27] | Fees paid | Renewal fee | 30.11.2012 | Renewal fee patent year 03 | 30.05.2014 | Renewal fee patent year 04 | 31.12.2014 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 30.11.2013 | 04 M06 Fee paid on 30.05.2014 | 30.11.2014 | 05 M06 Fee paid on 31.12.2014 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 10.11.2010 | AL | 29.07.2015 | AT | 29.07.2015 | BE | 29.07.2015 | BG | 29.07.2015 | CY | 29.07.2015 | CZ | 29.07.2015 | DK | 29.07.2015 | EE | 29.07.2015 | ES | 29.07.2015 | FI | 29.07.2015 | HR | 29.07.2015 | IT | 29.07.2015 | LT | 29.07.2015 | LV | 29.07.2015 | MC | 29.07.2015 | MK | 29.07.2015 | MT | 29.07.2015 | NL | 29.07.2015 | PL | 29.07.2015 | RO | 29.07.2015 | RS | 29.07.2015 | SE | 29.07.2015 | SI | 29.07.2015 | SK | 29.07.2015 | SM | 29.07.2015 | TR | 29.07.2015 | NO | 29.10.2015 | GR | 30.10.2015 | IE | 10.11.2015 | LU | 10.11.2015 | IS | 29.11.2015 | CH | 30.11.2015 | LI | 30.11.2015 | PT | 30.11.2015 | [2018/47] |
| Former [2018/30] | HU | 10.11.2010 | |
| AT | 29.07.2015 | ||
| BE | 29.07.2015 | ||
| BG | 29.07.2015 | ||
| CY | 29.07.2015 | ||
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| MC | 29.07.2015 | ||
| MK | 29.07.2015 | ||
| MT | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SI | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| SM | 29.07.2015 | ||
| TR | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IE | 10.11.2015 | ||
| LU | 10.11.2015 | ||
| IS | 29.11.2015 | ||
| CH | 30.11.2015 | ||
| LI | 30.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2017/38] | HU | 10.11.2010 | |
| AT | 29.07.2015 | ||
| BE | 29.07.2015 | ||
| BG | 29.07.2015 | ||
| CY | 29.07.2015 | ||
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| MC | 29.07.2015 | ||
| MT | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SI | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| SM | 29.07.2015 | ||
| TR | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IE | 10.11.2015 | ||
| LU | 10.11.2015 | ||
| IS | 29.11.2015 | ||
| CH | 30.11.2015 | ||
| LI | 30.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2017/03] | AT | 29.07.2015 | |
| BE | 29.07.2015 | ||
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| MC | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SI | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IE | 10.11.2015 | ||
| LU | 10.11.2015 | ||
| IS | 29.11.2015 | ||
| CH | 30.11.2015 | ||
| LI | 30.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/45] | AT | 29.07.2015 | |
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| MC | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SI | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IE | 10.11.2015 | ||
| LU | 10.11.2015 | ||
| IS | 29.11.2015 | ||
| CH | 30.11.2015 | ||
| LI | 30.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/36] | AT | 29.07.2015 | |
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| MC | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SI | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| LU | 10.11.2015 | ||
| IS | 29.11.2015 | ||
| CH | 30.11.2015 | ||
| LI | 30.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/34] | AT | 29.07.2015 | |
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| MC | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| LU | 10.11.2015 | ||
| IS | 29.11.2015 | ||
| CH | 30.11.2015 | ||
| LI | 30.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/31] | AT | 29.07.2015 | |
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| MC | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| LU | 10.11.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/28] | AT | 29.07.2015 | |
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| MC | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/23] | AT | 29.07.2015 | |
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RO | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| SK | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/22] | AT | 29.07.2015 | |
| CZ | 29.07.2015 | ||
| DK | 29.07.2015 | ||
| EE | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/21] | AT | 29.07.2015 | |
| DK | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| IT | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/20] | AT | 29.07.2015 | |
| DK | 29.07.2015 | ||
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/14] | AT | 29.07.2015 | |
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| NL | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/11] | AT | 29.07.2015 | |
| ES | 29.07.2015 | ||
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/10] | ES | 29.07.2015 | |
| FI | 29.07.2015 | ||
| HR | 29.07.2015 | ||
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| PL | 29.07.2015 | ||
| RS | 29.07.2015 | ||
| SE | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| IS | 29.11.2015 | ||
| PT | 30.11.2015 | ||
| Former [2016/09] | FI | 29.07.2015 | |
| LT | 29.07.2015 | ||
| LV | 29.07.2015 | ||
| NO | 29.10.2015 | ||
| GR | 30.10.2015 | ||
| Former [2016/08] | LT | 29.07.2015 | |
| NO | 29.10.2015 | ||
| Former [2016/07] | LT | 29.07.2015 | Cited in | International search | [X]CH681780 (PATRINOVE, et al) [X] 1-4,6-9,11-13,16,17 * column 1, lines 1-9 * * column 2, lines 22-27 * * column 2, line 45 - column 3, line 30 * * column 3, line 51 - column 4, line 18; claims 1, 4-6, 11, 13 *; | [X]WO0147507 (NOVARTIS AG [CH], et al) [X] 1-3,6-9,11-13,16,17 * page 9, paragraph l - page 10, paragraph 1 * * page 18, paragraph 2 - page 19, paragraph l * * page 21, paragraphs 1, 6 * * page 23, paragraph l * * page 24, paragraph 3 * * page 33, paragraph 4 - page 34, paragraph 1 * * page 39, paragraph 4 * * page 46, paragraph 2 * * example 12 * * claims 5, 6, 8 *; | [X]WO2009070331 (STC UNM [US], et al) [X] 1-4,6-13,15-17 * page 3, paragraph 2 * * page 5, paragraph l - page 6, paragraph 2 * * page 13, paragraph 3 * * page 17, paragraph 2 - page 18, paragraph 1 * * page 19, paragraphs 2-3 * * page 22, paragraph 2 * * claims 1-6, 9, 12, 14, 21 *; | [X]WO2004006842 (COMBINATORX INC [US]) [X] 1-4,6-13,15-17 * page 2, lines 14-17 * * page 4, line 23 - page 5, line 14 * * page 9, lines 9-20 * * page 13, line 18 - page 14, line 26 * * page 22, lines 6-9 * * table 1 * * page 27, line 14 - page 28, line 3 * * page 40, lines 5-8, 14-18 * * page 41, lines 11-14 * * page 42, lines 24-31 * * claims 10, 13-15, 17, 19, 36 *; | [XP]WO2010121141 (BIOGEN IDEC INC [US], et al) [XP] 18-20 * page 13, line 26 - page 14, line 6 * * examples 3, 4 * | [XY] - PILLOZZI SERENA ET AL, "A Macromolecular Signaling Complex Formed by CXCR4, VLA4 and hERG1 K+ Channels Mediates Bone Marrow-Induced Chemo-Resistance in Childhood Acute Lymphoblastic Leukemias: Shortcoming Effects of hERG1 Channels Inhibitors", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200811), Database accession no. PREV200900258328, XP002587813 [X] 1,4-8,11,13,16-20 * abstract * [Y] 2,3 | [ ] - BLOOD, 50TH ANNUAL MEETING OF THE AMERICAN- SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2008, (200811), vol. 112, no. 11, ISSN 0006-4971, pages 575 - 576 | [XY] - PILLOZZI SERENA ET AL, "Expression and role of hERG1 channels in pediatric acute lymphoblastic Leukemias: Shortcoming of drug resistance by hERG1 channel inhibitors in stoma-supported leukaemia cell cultures in vitro.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200711), Database accession no. PREV200800215997, XP002587814 [X] 1,6-8,11,13,16-20 * abstract * [Y] 2,3 | [ ] - BLOOD, 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, (200711), vol. 110, no. 11, Part 1, ISSN 0006-4971, page 222A | [XDY] - ARCANGELI A ET AL, "Targeting ion channels in cancer: A novel frontier in antineoplastic therapy", CURRENT MEDICINAL CHEMISTRY 2009 NL LNKD- DOI:10.2174/092986709787002835, (2009), vol. 16, no. 1, ISSN 0929-8673, pages 66 - 93, XP002587815 [XD] 1-3,6-8,11,13,15,17 * page 84, column 1, paragraphs 1-3; table 3; compounds E4031, sertindole * [Y] 2,3 DOI: http://dx.doi.org/10.2174/092986709787002835 | [X] - WANG LI ET AL, "Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, (200008), vol. 27, no. 8, ISSN 0305-1870, pages 587 - 593, XP002587816 [X] 1-3,6-13,15-17 * abstract * * page 590, column 2, paragraph 2 * * page 591, column 2, paragraph 3 * * figure 6 * * page 592, column 2, paragraphs 3-4 * | [X] - PAJEVA I K ET AL, "Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, (19960101), vol. 122, no. 1, ISSN 0171-5216, pages 27 - 40, XP008123342 [X] 1-4,6-8,11,13,16,17 * abstract * * page 28, column 2, paragraph 3 * * page 39, column 1, paragraph 4 * | [X] - SOLARY E ET AL, "SUFFICIENT LEVELS OF QUININE IN THE SERUM CIRCUMVENT THE MULTIDRUG RESISTANCE OF THE HUMAN LEUKEMIC CELL LINE K562-ADM", CANCER, (1991), vol. 68, no. 8, ISSN 0008-543X, pages 1714 - 1719, XP002587817 [X] 1-4,6-13,15-17 * abstract * * page 1715, column 1, paragraph 2 * * page 1716, column 1, paragraph 3 * * page 1718, column 1, paragraph l - column 2, paragraph 1 * * page 1718, column 2, paragraph 3 * | [X] - TSURUO T ET AL, "EFFECTS OF QUINIDINE AND RELATED COMPOUNDS ON CYTOTOXICITY AND CELLULAR ACCUMULATION OF VINCRISTINE AND ADRIAMYCIN IN DRUG-RESISTANT TUMOR CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, (19841001), vol. 44, no. 10, ISSN 0008-5472, pages 4303 - 4307, XP008038937 [X] 1-4,6-13,15-17 * abstract * * page 4303, column 2, paragraphs 3-5 * * page 4306, column 2, paragraph 3 * * table 4 * * page 4307, column 1, paragraph 1 * | [YD] - PILLOZZI S ET AL, "HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K SEP 2002 LNKD- PUBMED:12200695, (200209), vol. 16, no. 9, ISSN 0887-6924, pages 1791 - 1798, XP002587818 [YD] 2,3 * abstract * * page 1794, column 1, paragraph l * * page 1794, column 2, paragraph 2 * * figure 4 * | [XP] - PILLOZZI S ET AL, "Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 117, no. 3, doi:DOI:10.1162/BLOOD-2010-02-262591, ISSN 0006-4971, (20101103), pages 902 - 914, (20101103), XP008134468 [XP] 1-13,15-20 * abstract * * page 903, column 1, paragraph 2 * * page 903, column 2, paragraph 4 * * table 2 * * page 908, column 1, paragraph 2 - column 2, paragraph 1 * * figure 6 * * page 913, column 1, paragraph 1 * DOI: http://dx.doi.org/10.1162/blood-2010-02-262591 | [X] - ZENG ZHIHONG ET AL, "Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias", MOLECULAR CANCER THERAPEUTICS, (200612), vol. 5, no. 12, ISSN 1535-7163, pages 3113 - 3121, XP008139367 [X] 18-20 * abstract * * page 3115, column 2, paragraph 2 * * page 3117, column 2, paragraph 1 - page 3119, column 1, paragraph 1 * * figures 4, 5 * DOI: http://dx.doi.org/10.1158/1535-7163 | [X] - MANABE ATSUSHI ET AL, "Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells", BLOOD, (1994), vol. 83, no. 3, ISSN 0006-4971, pages 758 - 766, XP002649432 [X] 18,19 * page 758, column 2, paragraph 3 - page 759, column 1, paragraph 3 * | [X] - BURGER JAN A ET AL, "Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1", BLOOD, (20001015), vol. 96, no. 8, ISSN 0006-4971, pages 2655 - 2663, XP002649433 [X] 18,19 * page 2655, column 1, paragraph 2 * * page 2656, column 1, paragraph 3 - column 2, paragraph 2 * * page 2657, column 2, paragraph 3 - page 2658, column 1, paragraph 2 * * page 2661, column 1, paragraph 1 * | [X] - KONOPLEVA M ET AL, "Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins", LEUKEMIA, MACMILLAN PRESS LTD, US, (20020901), vol. 16, no. 9, doi:DOI:10.1038/SJ.LEU.2402608, ISSN 0887-6924, pages 1713 - 1724, XP002424990 [X] 18,19 * abstract * * page 1713, column 2, paragraph 1 - page 1714, column 1, paragraph 2 * * table 1 * * page 1720, column 2, paragraph 3 - page 1721, column 1, paragraph 1 * DOI: http://dx.doi.org/10.1038/sj.leu.2402608 | by applicant | - KONOPLEVA, M ET AL., "Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins", LEUKAEMIA, (2002), vol. 16, doi:doi:10.1038/sj.leu.2402608, pages 1713 - 1724, XP002424990 DOI: http://dx.doi.org/10.1038/sj.leu.2402608 | - ZENG, Z ET AL., "Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukaemias", MOL. CANCER THER., (2006), vol. 5, doi:doi:10.1158/1535-7163, pages 3113 - 3121, XP008139367 DOI: http://dx.doi.org/10.1158/1535-7163 | - TABE, Y ET AL., "Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukaemic cells by bone marrow-derived stromal cells", CANCER RES., (2007), vol. 67, pages 684 - 694 | - ARCANGELI, A; BECCHETTI, A., "Complex functional interaction between integrin receptors and ion channels", RENAS CEI.I BIOI., (2006), vol. 6, pages 63 I - 639 | - ARCANGELI, A ET AL., "Targeting ion channels in cancer: a novel frontier in antineoplastic therapy", CUR. MED. CHEM., (2009), vol. 16, no. 1, doi:doi:10.2174/092986709787002835, pages 66 - 93, XP002587815 DOI: http://dx.doi.org/10.2174/092986709787002835 | - ARCANGELI, A; BECCHETTI, A., "Complex functional interaction between integrin receptors and ion channels", TRENDS CELL BIOL., (2006), vol. 16, doi:doi:10.1016/j.tcb.2006.10.003, pages 631 - 639, XP025109624 DOI: http://dx.doi.org/10.1016/j.tcb.2006.10.003 | - PILLOZZI S. ET AL., "HERG potassium channels are constitutively expressed in primary human acute myeloid leukaemias and regulate cell proliferation of normal and leukaemic haemopoietic progenitors", LEUKAEMIA, (2002), vol. 16, pages 1791 - 1798 | - PILLOZZI S ET AL., "VEGFR-1 (FLT-1), ?1 integrin and hERG K+ channel form a macromolecular signaling complex in acute myeloid leukaemia: role in cell migration and clinical outcome", BLOOD, (2007), vol. 110, pages 1238 - 1250 | - WITCHEL HJ; HANCOX JC, "Familial and acquired Long QI synarome and the cardiac rapid delayed rectifier potassium current", CLIN EXP PHARMACOL PHYSIOL, (2000), vol. 27, doi:doi:10.1046/j.1440-1681.2000.03337.x, pages 753 - 766, XP001168606 DOI: http://dx.doi.org/10.1046/j.1440-1681.2000.03337.x | - ABRAMS RA ET AL., "Ficoll-Hypaque separation of bone marrow cells", BLOOD, (1985), vol. 66, pages 472 - 473 | - MANABE A. ET AL., BLOOD, (19920501), vol. 79, no. 9, pages 2370 - 7 | - CURRENT-CLIN EXP PHARMACOL PHYSIOL, (2000), vol. 27, pages 753 - 766 | - RA ABRAMS, "Ficoll-Hypaque separation of bone marrow cells", BLOOD, (1985), vol. 66, pages 472 - 473 | - ARCANGELI, A; BECCHETTI, A., "Complex functional interaction between integrin receptors and ion channels", TRENDS CEL.1 BIOL., (2006), vol. 16, doi:doi:10.1016/j.tcb.2006.10.003, pages 631 - 639, XP025109624 DOI: http://dx.doi.org/10.1016/j.tcb.2006.10.003 | - PILLOZZI S ET AL., "VEGFR-1 (FLT-1), b1 integrin and hERG K+ channel form a macromolecular signaling complex in acute myeloid leukaemia: role in cell migration and clinical outcome", BLOOD, (2007), vol. 110, pages 1238 - 1250 | - MANABE A. ET AL., "Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukaemia", BLOOD, (19920501), vol. 79, no. 9, pages 2370 - 7, XP055235079 |